07/03/2026
💜 Great news for the lupus community! Results published yesterday show that Obinutuzumab, a new treatment recently approved by NICE for lupus nephritis, also significantly reduces non-kidney lupus disease activity. Really promising progress in improving outcomes for people living with lupus. Stay tuned for more 🤓
Breaking lupus research news!
A Phase 3 study published in the The New England Journal of Medicine found that Gazyva® (obinutuzumab) from Genentech significantly reduced lupus disease activity and lowered glucocorticoid use in people with systemic lupus erythematosus (SLE).
Learn more about this breakthrough here: https://bit.ly/40d1DPB